Doximity, Inc. logo DOCS - Doximity, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 1
BUY 8
HOLD 13
SELL 1
STRONG
SELL 0
| PRICE TARGET: $27.63 DETAILS
HIGH: $50.00
LOW: $18.00
MEDIAN: $25.50
CONSENSUS: $27.63
UPSIDE: 24.40%

Stock News

Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026

Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.

Jul 16, 2026 12:01 PM • businesswire.com
Doximity Outranks OpenEvidence, Frontier Models in Independent Stanford-Harvard Study of Clinical AI Safety

Doximity Outranks OpenEvidence, Frontier Models in Independent Stanford-Harvard Study of Clinical AI Safety

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Doximity Ask, its HIPAA-compliant clinical AI platform, outperformed leading frontier AI models in the NOHARM (Numerous Options Harm Assessment for Risk in Medicine) benchmark, one of the most comprehensive independent evaluations of clinical AI safety to date. The study, conducted by ARISE, a clinical AI research team led by physicians from Stanford and.

Jul 15, 2026 10:26 AM • businesswire.com
Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories

Doximity: Everyone Is Focused On The Guidance While Missing The Valuation And AI Stories

Doximity issued conservative FY2027 guidance, projecting 4% revenue growth and a 49% adjusted EBITDA margin, triggering a post-earnings stock selloff. I view the selloff as a temporary dislocation and a compelling buying opportunity for value investors given DOCS's resilient core platform usage. Management emphasized record physician engagement and continued dominance of DOCS's core products despite macroeconomic and regulatory headwinds.

Jun 30, 2026 01:33 AM • seekingalpha.com
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm

DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Jun 11, 2026 08:00 AM • prnewswire.com (Hide legal announcements)
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm

DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Jun 08, 2026 08:44 AM • prnewswire.com (Hide legal announcements)

Price Targets